Seattle Genetics Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- SK Hynix's record profit misses forecasts, shares slump 13% despite robust AI chip demand
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Seattle Genetics (SGEN) Misses Q1 EPS by 19c, Revenues Miss; Maintains FY20 Sales Outlook
April 30, 2020 4:53 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q1 EPS of ($0.98), $0.19 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $198.51 million versus the consensus estimate of $207.14 million.
We have had a remarkable start to 2020, delivering record product sales in the first quarter that are now coming from both ADCETRIS and PADCEV. Notably,... More
